文献速递生殖医学

PIEZO-ICSI较标准ICSI提高受精率的前瞻性队列研究

PIEZO-ICSI increases fertilization rates compared with standard ICSI: a prospective cohort study.
PubMed 文献 · Reprod Biomed Online · 2021-05-31

该前瞻性病例匹配队列纳入69例需微注射且成熟卵母细胞≥6个的患者,比较PIEZO-ICSI与标准ICSI。PIEZO-ICSI组受精率显著更高、卵母细胞退变率与异常受精率更低,可冻存优质胚胎数更多;两组第5天胚胎发育及新鲜移植临床妊娠率无差异,但妊娠结局检验效能不足。

要点

  • PIEZO-ICSI受精率80.5±2.4%,显著高于标准ICSI的65.8±2.3%(P<0.0001)。
  • 卵母细胞退变率4.4±1.3% vs 8.6±1.2%(P=0.019),异常受精率2.9±1.1% vs 7.4±1.1%(P=0.003)。
  • 可冻存或移植的优质胚胎数3.8±0.2 vs 3.1±0.2(P=0.038),平均每周期多1个可用胚胎。

核心结论

  • PIEZO-ICSI较标准ICSI显著提高受精率,并增加可冻存胚胎数。
  • 受精率改善在≥38岁患者中获益最大。
  • 需进一步前瞻性研究评估累积妊娠率。

研究设计与样本

  • 纳入要求为成熟卵母细胞≥6个。
  • PIEZO-ICSI采用高速微注射钻孔穿透透明带和卵膜,将精子注入细胞质,区别于标准ICSI的切割动作。

主要发现

  • PIEZO-ICSI受精率80.5±2.4%,标准ICSI为65.8±2.3%(P<0.0001)。
  • 卵母细胞退变率4.4±1.3% vs 8.6±1.2%(P=0.019)。
  • 异常受精率2.9±1.1% vs 7.4±1.1%(P=0.003)。
  • 可冻存或移植的优质胚胎数3.8±0.2 vs 3.1±0.2(P=0.038)。
  • 第5天胚胎发育及新鲜移植临床妊娠率无差异(57.1% vs 60.0%),妊娠结局检验效能不足。

关键数值与推荐

  • 主要结局为受精率;次要结局包括卵母细胞退变、异常受精、胚胎冻存与胚胎利用。
  • PIEZO-ICSI组平均每周期比标准ICSI多1个可用胚胎。

临床怎么用

  • 对成熟卵母细胞数≥6个的微注射患者,可考虑PIEZO-ICSI以提高受精率并增加可冻存胚胎。
  • ≥38岁患者可能从PIEZO-ICSI的受精率改善中获益更明显。
  • 妊娠结局证据尚不充分,不能据此推断临床妊娠率优势。

局限性

  • 样本量69例,妊娠结局检验效能不足。
  • 为前瞻性病例匹配队列而非随机对照试验。
  • 未评估累积妊娠率,需进一步前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Is PIEZO-intracytoplasmic sperm injection (ICSI) coupled with a new novel operational fluid (perfluoro-n-octane) superior to standard ICSI? DESIGN: A cohort of patients (n = 69) undertaking microinjection were recruited between January and November 2019 and were then prospectively case-matched. Patients required six or more mature oocytes for inclusion in the study. PIEZO-ICSI uses high-speed microinjection drilling to penetrate the zona and oolemma and deposit the spermatozoa into the cytoplasm, compared with the traditional 'cutting' action of ICSI. The primary outcome was fertilization, with secondary outcomes including oocyte degeneration, abnormal fertilization, embryo cryopreservation and embryo utilization. RESULTS: PIEZO-ICSI resulted in significantly higher fertilization rates (80.5 ± 2.4% vs 65.8 ± 2.3%, P < 0.0001) and lower oocyte degeneration rates (4.4 ± 1.3% vs 8.6 ± 1.2%, P = 0.019) and abnormal fertilization rates (2.9 ± 1.1% vs 7.4 ± 1.1%; P = 0.003) compared with standard ICSI. This improvement in fertilization was of most benefit in patients aged ≥38 years. This increase in fertilization increased the number of good quality embryos that were available for cryopreservation/transfer (3.8 ± 0.2 vs 3.1 ± 0.2; P = 0.038), such that patients on average had one extra usable embryo per cycle compared with standard ICSI. There were no differences to Day 5 embryo development or clinical pregnancy from fresh embryo transfer (57.1% PIEZO-ICSI vs 60.0% ICSI) between microinjection methods, although pregnancy outcomes were underpowered. CONCLUSIONS: PIEZO-ICSI significantly increased fertilization rates, thereby increasing the number of embryos available for cryopreservation compared with standard ICSI. Further prospective studies assessing cumulative pregnancy rates are warranted.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Zander-Fox D, Lam K, Pacella-Ince L, et al. PIEZO-ICSI increases fertilization rates compared with standard ICSI: a prospective cohort study. Reprod Biomed Online. 2021. PMID: 34326006. doi:10.1016/j.rbmo.2021.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。